Skip to main content
PMC home page
American Journal of Human Genetics logoLink to American Journal of Human Genetics
. 1997 May;60(5):1031–1040.

BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2.

E L Schubert 1, M K Lee 1, H C Mefford 1, R H Argonza 1, J E Morrow 1, J Hull 1, J L Dann 1, M C King 1
PMCID: PMC1712449  PMID: 9150150

Abstract

In order to evaluate the role of inherited BRCA2 mutations in American families--particularly the appearance in America of European founder mutations--the BRCA2 coding sequence, 5' UTR, and 3' UTR were screened in 22 Caucasian American kindreds with four or more cases of breast or ovarian cancer. Six mutations were found that cause a premature-termination codon; four of them have been reported elsewhere, and two are novel. In the four families with previously seen mutations, the distinct lineages at high risk of cancer were of Dutch, German, Irish, and Ashkenazi Jewish ancestry; mutations in Europe reflect these ancestries. The families with novel mutations were Puerto Rican Hispanic (exon 9 deletion 995delCAAAT) and Ashkenazi Jewish (exon 11 deletion 6425delTT). Among female BRCA2-mutation carriers, risks of breast cancer were 32% by age 50 years, 67% by age 70 years, and 80% by age 90 years, yielding a lifetime risk similar to that for BRCA1 but an older distribution of ages at onset. BRCA2 families also included multiple cases of cancers of the male breast (six cases), ovary (three cases), fallopian tube (two cases), pancreas (three cases), bladder (two cases), and prostate (two cases). Among 17 Ashkenazi Jewish families with four or more breast or ovarian cancers, 9 families (including 3 with ovarian cancer and 1 with male breast cancer) carried none of the three ancient mutations in BRCA1 or BRCA2. To date, both BRCA2 and BRCA1 have been screened by SSCA, supplemented by the protein-truncation test, in 48 families with four or more breast or ovarian cancers. Mutations have been detected in BRCA1 in 33 families, in BRCA2 in 6 families, and in neither gene in 9 families, suggesting both the probable cryptic nature of some mutations and the likelihood of at least one other BRCA gene.

Full text

PDF
1031

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Claus E. B., Risch N., Thompson W. D. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet. 1991 Feb;48(2):232–242. [PMC free article] [PubMed] [Google Scholar]
  2. Couch F. J., Farid L. M., DeShano M. L., Tavtigian S. V., Calzone K., Campeau L., Peng Y., Bogden B., Chen Q., Neuhausen S. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet. 1996 May;13(1):123–125. doi: 10.1038/ng0596-123. [DOI] [PubMed] [Google Scholar]
  3. Ford D., Easton D. F., Bishop D. T., Narod S. A., Goldgar D. E. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994 Mar 19;343(8899):692–695. doi: 10.1016/s0140-6736(94)91578-4. [DOI] [PubMed] [Google Scholar]
  4. Foster K. A., Harrington P., Kerr J., Russell P., DiCioccio R. A., Scott I. V., Jacobs I., Chenevix-Trench G., Ponder B. A., Gayther S. A. Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer. Cancer Res. 1996 Aug 15;56(16):3622–3625. [PubMed] [Google Scholar]
  5. Friedman L. S., Gayther S. A., Kurosaki T., Gordon D., Noble B., Casey G., Ponder B. A., Anton-Culver H. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet. 1997 Feb;60(2):313–319. [PMC free article] [PubMed] [Google Scholar]
  6. Friedman L. S., Szabo C. I., Ostermeyer E. A., Dowd P., Butler L., Park T., Lee M. K., Goode E. L., Rowell S. E., King M. C. Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. Am J Hum Genet. 1995 Dec;57(6):1284–1297. [PMC free article] [PubMed] [Google Scholar]
  7. Gayther S. A., Mangion J., Russell P., Seal S., Barfoot R., Ponder B. A., Stratton M. R., Easton D. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet. 1997 Jan;15(1):103–105. doi: 10.1038/ng0197-103. [DOI] [PubMed] [Google Scholar]
  8. Hall J. M., Friedman L., Guenther C., Lee M. K., Weber J. L., Black D. M., King M. C. Closing in on a breast cancer gene on chromosome 17q. Am J Hum Genet. 1992 Jun;50(6):1235–1242. [PMC free article] [PubMed] [Google Scholar]
  9. Hall J. M., Lee M. K., Newman B., Morrow J. E., Anderson L. A., Huey B., King M. C. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990 Dec 21;250(4988):1684–1689. doi: 10.1126/science.2270482. [DOI] [PubMed] [Google Scholar]
  10. Katagiri T., Nakamura Y., Miki Y. Mutations in the BRCA2 gene in hepatocellular carcinomas. Cancer Res. 1996 Oct 15;56(20):4575–4577. [PubMed] [Google Scholar]
  11. Miki Y., Katagiri T., Kasumi F., Yoshimoto T., Nakamura Y. Mutation analysis in the BRCA2 gene in primary breast cancers. Nat Genet. 1996 Jun;13(2):245–247. doi: 10.1038/ng0696-245. [DOI] [PubMed] [Google Scholar]
  12. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P. A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L. M., Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994 Oct 7;266(5182):66–71. doi: 10.1126/science.7545954. [DOI] [PubMed] [Google Scholar]
  13. Neuhausen S., Gilewski T., Norton L., Tran T., McGuire P., Swensen J., Hampel H., Borgen P., Brown K., Skolnick M. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet. 1996 May;13(1):126–128. doi: 10.1038/ng0596-126. [DOI] [PubMed] [Google Scholar]
  14. Phelan C. M., Lancaster J. M., Tonin P., Gumbs C., Cochran C., Carter R., Ghadirian P., Perret C., Moslehi R., Dion F. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet. 1996 May;13(1):120–122. doi: 10.1038/ng0596-120. [DOI] [PubMed] [Google Scholar]
  15. Puget N., Torchard D., Serova-Sinilnikova O. M., Lynch H. T., Feunteun J., Lenoir G. M., Mazoyer S. A 1-kb Alu-mediated germ-line deletion removing BRCA1 exon 17. Cancer Res. 1997 Mar 1;57(5):828–831. [PubMed] [Google Scholar]
  16. Roa B. B., Boyd A. A., Volcik K., Richards C. S. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet. 1996 Oct;14(2):185–187. doi: 10.1038/ng1096-185. [DOI] [PubMed] [Google Scholar]
  17. Serova O. M., Mazoyer S., Puget N., Dubois V., Tonin P., Shugart Y. Y., Goldgar D., Narod S. A., Lynch H. T., Lenoir G. M. Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes? Am J Hum Genet. 1997 Mar;60(3):486–495. [PMC free article] [PubMed] [Google Scholar]
  18. Stratton M. R. Recent advances in understanding of genetic susceptibility to breast cancer. Hum Mol Genet. 1996;5(Spec No):1515–1519. doi: 10.1093/hmg/5.supplement_1.1515. [DOI] [PubMed] [Google Scholar]
  19. Szabo C. I., King M. C. Population genetics of BRCA1 and BRCA2. Am J Hum Genet. 1997 May;60(5):1013–1020. [PMC free article] [PubMed] [Google Scholar]
  20. Takahashi H., Chiu H. C., Bandera C. A., Behbakht K., Liu P. C., Couch F. J., Weber B. L., LiVolsi V. A., Furusato M., Rebane B. A. Mutations of the BRCA2 gene in ovarian carcinomas. Cancer Res. 1996 Jun 15;56(12):2738–2741. [PubMed] [Google Scholar]
  21. Tavtigian S. V., Simard J., Rommens J., Couch F., Shattuck-Eidens D., Neuhausen S., Merajver S., Thorlacius S., Offit K., Stoppa-Lyonnet D. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet. 1996 Mar;12(3):333–337. doi: 10.1038/ng0396-333. [DOI] [PubMed] [Google Scholar]
  22. Thorlacius S., Olafsdottir G., Tryggvadottir L., Neuhausen S., Jonasson J. G., Tavtigian S. V., Tulinius H., Ogmundsdottir H. M., Eyfjörd J. E. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet. 1996 May;13(1):117–119. doi: 10.1038/ng0596-117. [DOI] [PubMed] [Google Scholar]
  23. Tonin P., Weber B., Offit K., Couch F., Rebbeck T. R., Neuhausen S., Godwin A. K., Daly M., Wagner-Costalos J., Berman D. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med. 1996 Nov;2(11):1179–1183. doi: 10.1038/nm1196-1179. [DOI] [PubMed] [Google Scholar]
  24. Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., Collins N., Gregory S., Gumbs C., Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995 Dec 21;378(6559):789–792. doi: 10.1038/378789a0. [DOI] [PubMed] [Google Scholar]
  25. Wooster R., Neuhausen S. L., Mangion J., Quirk Y., Ford D., Collins N., Nguyen K., Seal S., Tran T., Averill D. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994 Sep 30;265(5181):2088–2090. doi: 10.1126/science.8091231. [DOI] [PubMed] [Google Scholar]

Articles from American Journal of Human Genetics are provided here courtesy of American Society of Human Genetics

RESOURCES